[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100590421":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":34,"centralContacts":38,"locations":47,"responsibleParty":60,"collaborators":43,"id":62,"slug":63,"hasResults":64,"nctId":65,"briefTitle":66,"officialTitle":67,"acronym":43,"eligibilityCriteria":68,"healthyVolunteers":64,"sex":69,"minAge":70,"maxAge":43,"enrollmentInfo":71,"targetDuration":43,"studyType":74,"phases":75,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":50,"whyStopped":43,"lastUpdateSubmitDate":85,"lastUpdatePostDateStruct":86,"startDateStruct":89,"completionDateStruct":90,"leadSponsor":92,"locationsCount":93},{"fullName":5,"class":6},"Tel-Aviv Sourasky Medical Center","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","ACTIVE_COMPARATOR","Patients treated with Metoprolol 25mg",[13],"Drug: Metoprolol (MET)",{"label":15,"type":16,"description":17,"interventionNames":18},"Placebo","PLACEBO_COMPARATOR","Patients treated with matching placebo",[19],"Drug: Plcacebo",[21,28],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Metoprolol (MET)","Administration of metoprolol 25 mg twice daily",[9],[27],"metoprolol 25mg",{"type":22,"name":29,"description":30,"armGroupLabels":31,"otherNames":32},"Plcacebo","Administration of matching placebo",[15],[33],"placebo",[35],{"name":36,"affiliation":5,"role":37},"Yishay Szekely, MD","PRINCIPAL_INVESTIGATOR",[39,45],{"name":40,"role":41,"phone":42,"phoneExt":43,"email":44},"Shir Frydman, MD","CONTACT","0544267898",null,"shirfrydman@gmail.com",{"name":36,"role":41,"phone":43,"phoneExt":43,"email":46},"yishay.szekely@gmail.com",[48],{"facility":49,"status":50,"city":51,"state":43,"zip":43,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":43},"Tel Aviv Sourasky Medical center","RECRUITING","Tel Aviv","Israel","IL",{"type":55,"coordinates":56},"Point",[57,58],34.78057,32.08088,{"lat":58,"lon":57},{"type":61,"investigatorFullName":43,"investigatorTitle":43,"investigatorAffiliation":43,"oldNameTitle":43,"oldOrganization":43},"SPONSOR","100590421","early-beta-blocker-administration-in-stemi-patients-with-scai-b-status-100590421",false,"NCT06967194","Early Beta Blocker Administration in STEMI Patients With SCAI B Status","Early Beta-Blocker Administration in Patients With ST Segment Elevation Myocardial Infraction and SCAI B Status","Inclusion Criteria:\n\n* Diagnosis of ST-segment elevation myocardial infarction (STEMI) confirmed by ECG, clinical signs, and coronary catheterization.\n* Post-catheterization patients classified as SCAI B upon admission to the unit, defined by the presence of tachycardia and\u002For hypotension without signs of hypoperfusion (i.e., normal lactate levels, normal capillary refill, preserved mental status, and adequate urine output \\>0.5 mL\u002Fkg\u002Fhour).\n* Age 18 years or older.\n* Mentally competent to provide informed consent, understand the study procedures, and comply with medical recommendations.\n\nExclusion Criteria:\n\n* Pregnancy.\n* Inability to provide informed consent.\n* Evidence of pulmonary edema.\n* Bradycardia (heart rate \\\u003C60 beats per minute).\n* PR interval \\>240 milliseconds.\n* Second- or third-degree atrioventricular (AV) block.\n* Active asthma.\n* Known hypersensitivity to metoprolol.","ALL","18 Years",{"count":72,"type":73},200,"ESTIMATED","INTERVENTIONAL",[76],"NA","This study is looking at how a medication called beta-blockers (metoprolol) affects patients with a heart attack (STEMI) who are in the cardiac intensive care unit.\n\nWhen patients are admitted to the unit, they will be randomly placed in one of two groups. One group will get the metoprolol medication, and the other will receive a placebo (a harmless pill that looks like the real medication). All other treatments will be the same for both groups.\n\nDuring the study, which is 72 hours long, patients will be monitored for blood pressure, heart rate, and lactate levels alterations.\n\nThe main goal is to see if the medication helps improve patients condition or prevent it from getting worse. patients safety is a top priority, and if needed, the doctors can stop the study at any time if there are concerns.",[79,80],"ST Segment Elevation Myocardial Infarction (STEMI)","Cardiogenic Shock Post Myocardial Infarction",[82,83,84],"acute MI","stemi","beta blockers","2025-05-21",{"date":87,"type":88},"2025-05-28","ACTUAL",{"date":85,"type":88},{"date":91,"type":73},"2027-06",{"name":5,"class":6},1]